Biomarkers for ADC Selection in NSCLC: Latest Advances and Future Directions
Автор: Infinite Ideas Space
Загружено: 2025-11-15
Просмотров: 5
Описание:
Dive into the latest advancements in antibody-drug conjugates (ADCs) for non-small cell lung cancer (NSCLC). Learn why additional biomarkers are crucial for personalizing ADC treatments from expert Benjamin P. Levy, MD.
Explore HER2-targeted ADCs like fam-trastuzumab deruxtecan-nxki (Enhertu) and trastuzumab rezetecan, including key trial data from DESTINY-Lung02 and HORIZON-Lung.
Discover TROP2-directed therapies such as datopotamab deruxtecan-dlnk (Datroway) and MET-targeted telisotuzumab vedotin-tllv (Emrelis), with insights on efficacy, safety, and approvals.
Uncover emerging biomarkers like TROP2 QCS-NMR scoring using AI for better treatment outcomes. Understand the role of ADCs in reshaping lung cancer therapy and the need for preclinical and clinical studies.
Keywords: ADC NSCLC, antibody-drug conjugates lung cancer, HER2 ADC, TROP2 ADC, MET ADC, biomarkers lung cancer, Enhertu NSCLC, Datroway EGFR NSCLC.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
![Divine Music - The Year Mix Vol.10 [Chill & Ethnic Deep 2025]](https://imager.clipsaver.ru/Q3XBH_FhuKY/max.jpg)
